Mizukami J et al. |
Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. |
2002 |
Mol. Cell. Biol. |
pmid:11809792
|
Mochizuki S et al. |
Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats. |
2002 |
J. Bone Miner. Metab. |
pmid:11810411
|
Childs LM et al. |
In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. |
2002 |
J. Bone Miner. Res. |
pmid:11811549
|
Holloway WR et al. |
Leptin inhibits osteoclast generation. |
2002 |
J. Bone Miner. Res. |
pmid:11811550
|
Coen G et al. |
Serum osteoprotegerin and renal osteodystrophy. |
2002 |
Nephrol. Dial. Transplant. |
pmid:11812872
|
Viereck V et al. |
Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts. |
2002 |
J. Cell. Biochem. |
pmid:11835398
|
Wise GE et al. |
Inhibition of osteoclastogenesis by the secretion of osteoprotegerin in vitro by rat dental follicle cells and its implications for tooth eruption. |
2002 |
Arch. Oral Biol. |
pmid:11839361
|
Scatena M and Giachelli C |
The alpha(v)beta3 integrin, NF-kappaB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis. |
2002 |
Trends Cardiovasc. Med. |
pmid:11852256
|
Hofbauer LC and Kühne CA |
Cytokine inhibition: a new therapeutic avenue for skeletal diseases. |
2002 |
Drug Discov. Today |
pmid:11854049
|
Viereck V et al. |
Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. |
2002 |
Biochem. Biophys. Res. Commun. |
pmid:11855844
|
Romas E et al. |
Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. |
2002 |
Bone |
pmid:11856640
|
Theill LE et al. |
RANK-L and RANK: T cells, bone loss, and mammalian evolution. |
2002 |
Annu. Rev. Immunol. |
pmid:11861618
|
Roux S et al. |
RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. |
2002 |
Am. J. Clin. Pathol. |
pmid:11863217
|
Green EA et al. |
Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. |
2002 |
Immunity |
pmid:11869680
|
Faucheux C et al. |
Nuclear localization of type I parathyroid hormone/parathyroid hormone-related protein receptors in deer antler osteoclasts: evidence for parathyroid hormone-related protein and receptor activator of NF-kappaB-dependent effects on osteoclast formation in regenerating mammalian bone. |
2002 |
J. Bone Miner. Res. |
pmid:11874237
|
Kazama JJ et al. |
Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. |
2002 |
Am. J. Kidney Dis. |
pmid:11877571
|
Haas M et al. |
Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. |
2002 |
Am. J. Kidney Dis. |
pmid:11877577
|
Feige U |
Osteoprotegerin. |
2001 |
Ann. Rheum. Dis. |
pmid:11890662
|
Holen I et al. |
Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. |
2002 |
Cancer Res. |
pmid:11912131
|
Mori H et al. |
RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse. |
2002 |
Histochem. Cell Biol. |
pmid:11914926
|
Goater JJ et al. |
Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis. |
2002 |
J. Orthop. Res. |
pmid:11918293
|
Roux S et al. |
RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. |
2002 |
Br. J. Haematol. |
pmid:11918537
|
Oshiro T et al. |
Osteoclast induction in periodontal tissue during experimental movement of incisors in osteoprotegerin-deficient mice. |
2002 |
Anat. Rec. |
pmid:11920384
|
Redlich K et al. |
Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. |
2002 |
Arthritis Rheum. |
pmid:11920416
|
Khosla S et al. |
Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. |
2002 |
J. Clin. Endocrinol. Metab. |
pmid:11932280
|
Kanematsu M et al. |
Vector-averaged gravity regulates gene expression of receptor activator of NF-kappaB (RANK) ligand and osteoprotegerin in bone marrow stromal cells via cyclic AMP/protein kinase A pathway. |
2002 |
Bone |
pmid:11934645
|
Li X et al. |
Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice. |
2002 |
Bone |
pmid:11934647
|
Jain RG and Lenhard JM |
Select HIV protease inhibitors alter bone and fat metabolism ex vivo. |
2002 |
J. Biol. Chem. |
pmid:11937496
|
Schoppet M et al. |
RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. |
2002 |
Arterioscler. Thromb. Vasc. Biol. |
pmid:11950689
|
Ariyasu T et al. |
Trehalose augments osteoprotegerin production in the FHs74Int human intestinal epithelial cell line. |
2002 |
In Vitro Cell. Dev. Biol. Anim. |
pmid:11963965
|
Bateman TA and Countryman S |
Osteoprotegerin and bone loss associated with spaceflight. |
2002 |
Drug Discov. Today |
pmid:11965392
|
Inoue D and Matsumoto T |
[Recent advances in basic research of bone metabolism]. |
2002 |
Nippon Rinsho |
pmid:11979916
|
Suzuki Y et al. |
[Bone destruction and bone loss in rheumatoid arthritis--mechanism, prevention and treatment]. |
2002 |
Nippon Rinsho |
pmid:11979937
|
Inoue D |
[Recent advances in research of bone resorption]. |
2002 |
Nippon Rinsho |
pmid:11979946
|
Udagawa N and Takahashi N |
[Possible role of receptor activator of NF-kappa B ligand(RANKL) in osteoclast differentiation and function]. |
2002 |
Nippon Rinsho |
pmid:11979968
|
Tsuda E |
[Osteoclastogenesis inhibitory factor (OCIF)/OPG (a novel therapeutic candidate for the treatment of metabolic bone diseases)]. |
2002 |
Nippon Rinsho |
pmid:11979969
|
Koshihara Y |
[Recent progress of bone cell culture system (review)]. |
2002 |
Nippon Rinsho |
pmid:11979973
|
Hasegawa T et al. |
Human periodontal ligament cells derived from deciduous teeth induce osteoclastogenesis in vitro. |
2002 |
Tissue Cell |
pmid:11989970
|
Evdokiou A et al. |
Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. |
2002 |
Int. J. Cancer |
pmid:11992538
|
Corey E et al. |
Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. |
2002 |
Prostate |
pmid:11992617
|
Gruber R et al. |
Platelet-released supernatants stimulate formation of osteoclast-like cells through a prostaglandin/RANKL-dependent mechanism. |
2002 |
Bone |
pmid:11996911
|
de Hooge AS et al. |
Adenoviral transfer of murine oncostatin M elicits periosteal bone apposition in knee joints of mice, despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-kappa B ligand. |
2002 |
Am. J. Pathol. |
pmid:12000725
|
Bosshart H |
Expression of survival receptors in Hodgkin disease cell lines. |
2002 |
Blood |
pmid:12001908
|
Ono K et al. |
Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. |
2002 |
J. Bone Miner. Res. |
pmid:12009007
|
Iida-Klein A et al. |
Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. |
2002 |
J. Bone Miner. Res. |
pmid:12009011
|
Jiang Y et al. |
Bacteria induce osteoclastogenesis via an osteoblast-independent pathway. |
2002 |
Infect. Immun. |
pmid:12011008
|
Granchi D et al. |
Bone cement extracts modulate the osteoprotegerin/osteoprotegerin-ligand expression in MG63 osteoblast-like cells. |
2002 |
Biomaterials |
pmid:12013183
|
Li X et al. |
Prostaglandin receptor EP2 mediates PGE2 stimulated hypercalcemia in mice in vivo. |
2002 |
Prostaglandins Other Lipid Mediat. |
pmid:12013525
|
Treuheit MJ et al. |
Inverse relationship of protein concentration and aggregation. |
2002 |
Pharm. Res. |
pmid:12033388
|
Lossdörfer S et al. |
Immunohistochemical localization of receptor activator of nuclear factor kappaB (RANK) and its ligand (RANKL) in human deciduous teeth. |
2002 |
Calcif. Tissue Int. |
pmid:12043011
|
Ueland T et al. |
Effects of 12 months of GH treatment on cortical and trabecular bone content of IGFs and OPG in adults with acquired GH deficiency: a double-blind, randomized, placebo-controlled study. |
2002 |
J. Clin. Endocrinol. Metab. |
pmid:12050246
|
Sasaki N et al. |
Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis. |
2002 |
Bone |
pmid:12052453
|
Brändström H et al. |
A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function. |
2002 |
Biochem. Biophys. Res. Commun. |
pmid:12054556
|
Wittrant Y et al. |
Osteoprotegerin differentially regulates protease expression in osteoclast cultures. |
2002 |
Biochem. Biophys. Res. Commun. |
pmid:12054560
|
Penno H et al. |
Osteoprotegerin secretion from prostate cancer is stimulated by cytokines, in vitro. |
2002 |
Biochem. Biophys. Res. Commun. |
pmid:12054622
|
Fu M et al. |
Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin gene expression in human aortic smooth muscle cells. |
2002 |
Biochem. Biophys. Res. Commun. |
pmid:12056809
|
Zhang J et al. |
PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. |
2002 |
FEBS Lett. |
pmid:12067713
|
Nakamura H et al. |
Localization of osteoprotegerin (OPG) on bone surfaces and cement lines in rat tibia. |
2002 |
J. Histochem. Cytochem. |
pmid:12070273
|
Wynne F et al. |
Investigation of the genetic influence of the OPG, VDR (Fok1), and COLIA1 Sp1 polymorphisms on BMD in the Irish population. |
2002 |
Calcif. Tissue Int. |
pmid:12073153
|
Kim YH et al. |
Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. |
2002 |
Exp. Mol. Med. |
pmid:12085990
|
Khosla S et al. |
Correlates of osteoprotegerin levels in women and men. |
2002 |
Osteoporos Int |
pmid:12086350
|
Price PA et al. |
Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment. |
2002 |
J. Bone Miner. Res. |
pmid:12096831
|
Xing L et al. |
NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. |
2002 |
J. Bone Miner. Res. |
pmid:12096833
|
Zou W and Bar-Shavit Z |
Dual modulation of osteoclast differentiation by lipopolysaccharide. |
2002 |
J. Bone Miner. Res. |
pmid:12096834
|
Koyama H et al. |
Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. |
2002 |
J. Bone Miner. Res. |
pmid:12096835
|
Langdahl BL et al. |
Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. |
2002 |
J. Bone Miner. Res. |
pmid:12096838
|
Zhang J et al. |
Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. |
2002 |
J. Bone Miner. Res. |
pmid:12096839
|
Saidenberg Kermanac'h N et al. |
Osteoprotegerin and inflammation. |
2002 Apr-Jun |
Eur. Cytokine Netw. |
pmid:12101070
|
Katagiri T and Takahashi N |
Regulatory mechanisms of osteoblast and osteoclast differentiation. |
2002 |
Oral Dis |
pmid:12108759
|
Lee SK and Lorenzo JA |
Regulation of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures. |
2002 |
Bone |
pmid:12110442
|
Shioi A et al. |
Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages. |
2002 |
Circ. Res. |
pmid:12114316
|
Lipton A et al. |
Serum osteoprotegerin levels in healthy controls and cancer patients. |
2002 |
Clin. Cancer Res. |
pmid:12114435
|
Biskobing DM et al. |
Novel therapeutic options for osteoporosis. |
2002 |
Curr Opin Rheumatol |
pmid:12118183
|
Whyte MP et al. |
Osteoprotegerin deficiency and juvenile Paget's disease. |
2002 |
N. Engl. J. Med. |
pmid:12124406
|
Krane SM |
Genetic control of bone remodeling--insights from a rare disease. |
2002 |
N. Engl. J. Med. |
pmid:12124412
|
Ziolkowska M et al. |
High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. |
2002 |
Arthritis Rheum. |
pmid:12124857
|
Campagnuolo G et al. |
Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. |
2002 |
Arthritis Rheum. |
pmid:12124878
|
Sakata M et al. |
Osteoprotegerin levels increased by interleukin-1beta in human periodontal ligament cells are suppressed through prostaglandin E(2) synthesized de novo. |
2002 |
Cytokine |
pmid:12126649
|
Petersson M et al. |
Oxytocin stimulates proliferation of human osteoblast-like cells. |
2002 |
Peptides |
pmid:12126740
|
Grisar J et al. |
Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. |
2002 |
J. Rheumatol. |
pmid:12136902
|
Chen XW et al. |
Isoflavones regulate interleukin-6 and osteoprotegerin synthesis during osteoblast cell differentiation via an estrogen-receptor-dependent pathway. |
2002 |
Biochem. Biophys. Res. Commun. |
pmid:12150965
|
Hofbauer LC et al. |
Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. |
2002 |
Eur. J. Endocrinol. |
pmid:12153751
|
Mundy GR |
Metastasis to bone: causes, consequences and therapeutic opportunities. |
2002 |
Nat. Rev. Cancer |
pmid:12154351
|
Lorget F et al. |
Lactoferrin reduces in vitro osteoclast differentiation and resorbing activity. |
2002 |
Biochem. Biophys. Res. Commun. |
pmid:12163011
|
Geoffroy V et al. |
High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage. |
2002 |
Mol. Cell. Biol. |
pmid:12167715
|
Uemura H et al. |
Serum osteoprotegerin/osteoclastogenesis-inhibitory factor during pregnancy and lactation and the relationship with calcium-regulating hormones and bone turnover markers. |
2002 |
J. Endocrinol. |
pmid:12176675
|
Ragab AA et al. |
Cytokines synergistically induce osteoclast differentiation: support by immortalized or normal calvarial cells. |
2002 |
Am. J. Physiol., Cell Physiol. |
pmid:12176725
|
Ulrich-Vinther M et al. |
Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. |
2002 |
J Bone Joint Surg Am |
pmid:12177271
|
Ohmori H et al. |
Linkage and association analyses of the osteoprotegerin gene locus with human osteoporosis. |
2002 |
J. Hum. Genet. |
pmid:12181640
|
Armstrong AP et al. |
A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. |
2002 |
J. Biol. Chem. |
pmid:12185073
|
Cundy T et al. |
A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. |
2002 |
Hum. Mol. Genet. |
pmid:12189164
|
Lee SK et al. |
1,25(OH)2 vitamin D3-stimulated osteoclast formation in spleen-osteoblast cocultures is mediated in part by enhanced IL-1 alpha and receptor activator of NF-kappa B ligand production in osteoblasts. |
2002 |
J. Immunol. |
pmid:12193704
|
Fujita T et al. |
SPARC stimulates the synthesis of OPG/OCIF, MMP-2 and DNA in human periodontal ligament cells. |
2002 |
J. Oral Pathol. Med. |
pmid:12201246
|
Juji T et al. |
A novel therapeutic vaccine approach, targeting RANKL, prevents bone destruction in bone-related disorders. |
2002 |
J. Bone Miner. Metab. |
pmid:12203031
|
Jono S et al. |
Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. |
2002 |
Circulation |
pmid:12208791
|
Sedger LM et al. |
Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. |
2002 |
Eur. J. Immunol. |
pmid:12209637
|
Hofbauer LC et al. |
Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. |
2002 |
J. Cell. Biochem. |
pmid:12210731
|
Kondo H et al. |
Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. |
2002 |
J. Bone Miner. Res. |
pmid:12211438
|
Hofbauer LC and Schoppet M |
Osteoprotegerin gene polymorphism and the risk of osteoporosis and vascular disease. |
2002 |
J. Clin. Endocrinol. Metab. |
pmid:12213849
|
Arko B et al. |
Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis. |
2002 |
J. Clin. Endocrinol. Metab. |
pmid:12213850
|